HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS

多发性硬化症急性加重中的 HU23F2G

• 批准号: 6281706
• 负责人: Jerry Saul Wolinsky
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281706
• 关键词: clinical research; drug screening /evaluation; hormone therapy; human subject; human therapy evaluation; immunotherapy; methylprednisolone; monoclonal antibody; multiple sclerosis

The study is designed to evaluate the efficacy & safety of Hu23F2G administered intravenously to patients with acute exacerbations of multiple sclerosis (MS) as compared to placebo and corticosteroid treatment. Hu23F2G is a humanized anti-CD18 monoclonal antibody which has been effective in a non-human primate experimental model of MS. This is a Phase 2 study in which patients will be randomized to treatment for 3 days with placebo, methylprednisoline, or Hu23F2G at 1 or 2 mg/kg. Subjects will be followed for 1 year after treatment.

本研究旨在评价Hu23F2G的有效性和安全性